Lebrikizumab Monotherapy Safe, Effective for AD During Induction Lebrikizumab Monotherapy Safe, Effective for AD During Induction

Results"show a rapid onset of action in multiple domains of the disease, such as skin clearance and itch," after 16 weeks of treatment with lebrikizumab, an interleukin-13 inhibitor.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Dermatology News Source Type: news